# Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

> **NCT02838316** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Peter Belafsky, MD** · enrollment: 18 (actual)

## Conditions studied

- Oropharyngeal Dysphagia

## Interventions

- **DRUG:** Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)

## Key facts

- **NCT ID:** NCT02838316
- **Lead sponsor:** Peter Belafsky, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-24
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02838316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02838316, "Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02838316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*